Finoriq research workspace
GILEAD SCIENCES, INC. (GILD) Institutional Holdings & 13F Ownership
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes. Review GILD institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Company
- GILEAD SCIENCES, INC. (GILD)
- Ticker
- GILD
- Market Cap
- $165.7B
- Latest Price
- $133.49
- Industry
- Biotech & Pharma
GILEAD SCIENCES, INC. (GILD) Top Institutional Holders
Top current 13F holders indexed for GILEAD SCIENCES, INC. (GILD). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Dodge & Cox (advisor level)CIK 0000200217 | $3.4B | 1.9% | Filing2026-05-14 |
| 2 | Joel GreenblattCIK 0001510387 | $52.4M | 0.16% | Filing2026-05-15 |
| 3 | John RogersCIK 0000936753 | $28.2M | 0.32% | Filing2026-05-14 |
| 4 | Ray DalioCIK 0001350694 | $25.2M | 0.11% | Filing2026-05-15 |
| 5 | Ron BaronCIK 0001017918 | $4.2M | 0.01% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.